Parametric Portfolio Associates’s Y-mAbs Therapeutics YMAB Stock Holding History

Parametric Portfolio Associates’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$253K	Buy	21,265 +6,131	+41%	+$63K	﹤0.01%	3346
2021 Q4	$245K	Buy	15,134 +4,083	+37%	+$87.3K	﹤0.01%	3351
2021 Q3	$315K	Sell	11,051 -36,423	-77%	-$1.15M	﹤0.01%	3283
2021 Q2	$1.6M	Buy	47,474 +30,604	+181%	+$982K	﹤0.01%	2550
2021 Q1	$510K	Sell	16,870 -2,726	-14%	-$112K	﹤0.01%	3492
2020 Q4	$970K	Sell	19,596 -132	-0.7%	-$6.11K	﹤0.01%	3071
2020 Q3	$757K	Buy	19,728 +1,017	+5%	+$40.5K	﹤0.01%	3076
2020 Q2	$808K	Buy	+18,711	New	+$708K	﹤0.01%	3033

Other funds holding YMAB

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parametric Portfolio Associates's YMAB Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Y-mAbs Therapeutics (YMAB) stake by 41% in Q1 2022, buying an estimated $63K and bringing the position to 21,265 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #3346.

Parametric Portfolio Associates first reported a position in YMAB in Q2 2020 and has held it in 8 quarters since. The position peaked at $1.6M in Q2 2021. 88 funds tracked by Wall St. Rank hold YMAB as of Q1 2022.

Parametric Portfolio Associates held 21,265 shares of Y-mAbs Therapeutics worth $253K as of Q1 2022.
Parametric Portfolio Associates bought 6,131 Y-mAbs Therapeutics shares in Q1 2022, an estimated $63K.
Y-mAbs Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3346 holding.
Parametric Portfolio Associates first reported a position in Y-mAbs Therapeutics in Q2 2020 and has held it in 8 quarters since.
Parametric Portfolio Associates's Y-mAbs Therapeutics position peaked at $1.6M in Q2 2021.
88 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.